Ariad Pharmaceuticals (ARIA) Posts Q2 Loss of 36c; Revs Light
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $25.78 -0.96%
Financial Fact:
Other income (expense), net: -5.17M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Other income (expense), net: -5.17M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) reported Q2 loss of ($0.36), $0.18 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $66 thousand versus the consensus estimate of $930 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exchange Traded Concepts and ARIAM Global launch ARIA an Actively Managed ETF Led by a Portfolio Manager with a Ph.D. in AI and Computer Science
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
